A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn's disease in remission. [Studio, multicentrico di fase II, di estensione a lungo termine, randomizzato, in doppio cieco, controllato vs placebo per valutare la sicurezza e la tollerabilita' di GED-0301 40 mg, per il mantenimento della remissione del Morbo di Crohn] [EXTENSION OF 700213839]

Trial Profile

A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn's disease in remission. [Studio, multicentrico di fase II, di estensione a lungo termine, randomizzato, in doppio cieco, controllato vs placebo per valutare la sicurezza e la tollerabilita' di GED-0301 40 mg, per il mantenimento della remissione del Morbo di Crohn] [EXTENSION OF 700213839]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2013

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms IGON-2
  • Most Recent Events

    • 20 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top